(Total Views: 762)
Posted On: 07/20/2020 10:17:12 AM
Post# of 155780
“All on preliminary results in a somewhat less than robust study.”
Careful what you say about Synairgen’s trial as the design seems very similar to that of the M2M trial for leronlimab. Synairgen states the trial had 101 patients and was double-blind and placebo controlled, again, similar to the M2M trial. The full data needs to be released, as well as trial methodology, etc., but the results from our M2M could be very similar and received in a similar manner.
So, If Synairgen’s trial is, “somewhat less than robust,” to you, then what does that make the M2M trial?
Careful what you say about Synairgen’s trial as the design seems very similar to that of the M2M trial for leronlimab. Synairgen states the trial had 101 patients and was double-blind and placebo controlled, again, similar to the M2M trial. The full data needs to be released, as well as trial methodology, etc., but the results from our M2M could be very similar and received in a similar manner.
So, If Synairgen’s trial is, “somewhat less than robust,” to you, then what does that make the M2M trial?
(3)
(0)
